The acquired metallo-b-lactamases represent a significant clinical threat due to their unrivalled hydrolysis spectrum and their resistance to therapeutic inhibitors of b-lactamase. In this study, we identified plasmid-and integron-borne bla IMP-11 in clinical isolates of Escherichia coli and Klebsiella pneumoniae. The bla IMP-11 gene cassette was carried by a typical class 1 integron together with aacA1 and orfG gene cassettes. The integron, intI1-bla IMP-11 -aacA1-orfG-qacED1-sul1, was easily transferred by intraspecies and intergenus conjugation of bacteria, indicating that the integron is located on a transferable plasmid. The integrated genes were preceded by TGGACA-N 17 -TAAACT, a hybrid P c promoter. Similar to the wild-type donors, the transconjugants also showed reduced susceptibility or resistance to carbapenems, amikacin and kanamycin. The identical integron was detected in four bacterial strains which were genetically different but were isolated from infant inpatients in the same paediatric department. These results demonstrate the colonization of the plasmid-and integron-borne bla IMP-11 and aacA1 in the hospital environment, highlighting the importance of surveying and controlling the spread of such resistance determinants in nosocomial pathogens.
INTRODUCTION
Carbapenems are potent, broad-spectrum b-lactams and are resistant to hydrolysis by most b-lactamases, including extended-spectrum b-lactamases and AmpC b-lactamases (Bradford, 2001; Jacoby, 2009) . Since the introduction of imipenem, the first carbapenem antibiotic, in the 1980s, meropenem, panipenem, biapenem, ertapenem and doripenem have been developed to combat severe infections caused by multi-resistant pathogens (Lister, 2007; Bassetti et al., 2009) . However, the emergence of carbapenemases, especially metallo-b-lactamases (MBLs), has begun to limit their use in the clinic (Queenan & Bush, 2007; Walsh et al., 2005) .
MBLs represent the most versatile family of b-lactamases, owing to the fact that they hydrolyse almost all b-lactam antibiotics, with the exception of aztreonam, and are resistant to the clinically available b-lactamase inhibitors, such as sulbactam, clavulanate and tazobactam (Walsh et al., 2005) . Although MBLs are susceptible to EDTA and sodium mercaptoacetate (SMA), these agents cannot be used as b-lactamase inhibitors for clinical treatment, due to their toxicities. EDTA and SMA are merely used in an inhibitor-based method to detect MBL-producing strains in the clinical laboratory (Arakawa et al., 2000) .
Eight families of acquired MBLs, namely IMPs, VIMs, SPM-1, GIM-1, AIM-1, SIM-1, NDM-1 and DIM-1, have been found (Zhao & Hu, 2010; Lee et al., 2005; Yong et al., 2009; Poirel et al., 2010) . IMP-1 was the first acquired MBL discovered, in a clinical isolate of Pseudomonas aeruginosa in Japan (Watanabe et al., 1991) . To date, 30 IMP-type blactamases have been identified in at least 26 species of clinically important Gram-negative bacilli from more than 24 countries/regions (Zhao & Hu, 2011a; Jacoby & Bush, 2011) .
IMP-11 was originally found in clinical isolates of P. aeruginosa and Acinetobacter baumannii in Japan, and the nucleotide sequence of bla IMP-11 was reported in 2001 in the GenBank database (accession numbers AB074437 and AB074436). Subsequently, IMP-11 was also detected in clinical isolates of Serratia marcescens (Jones et al., 2004) , Klebsiella pneumoniae (Sugimoto et al., 2010) and Enterobacter cloacae (Takahashi et al., 2010) . However, few original articles or information about the genetic environment of the encoding gene are available for IMP-11. In this study, we focused on the genetic environment and nosocomial spread of the bla IMP-11 gene which was identified in clinical isolates of Escherichia coli and K. pneumoniae.
METHODS
Bacterial strains and reagents. Three strains of Escherichia coli (E0702, E0703 and E0802) and one strain of Klebsiella pneumoniae (K0709) were isolated from inpatients through routine bacterial culture and detection in the clinical laboratory at Showa University Northern Yokohama Hospital, Yokohama, Japan, during September 2007 and August 2008. The following reagents were purchased from the indicated commercial sources: imipenem (IPM) (US Pharmacopeia); biapenem (BIPM), ceftazidime (CAZ) and meropenem (MEPM) (LKT Laboratories); panipenem (PAPM) (Sankyo Organic Chemicals); amikacin (AMK), cefotaxime and streptomycin (Sigma); kanamycin (KAN) (Invitrogen); clavulanate (CAV) and sodium mercaptoacetate (SMA) (Wako Pure Chemical Industries).
Susceptibility testing. The susceptibilities of bacteria to various antibiotics were expressed as minimum inhibitory concentration (MIC). MICs were determined by a broth microdilution method according to the Clinical and Laboratory Standards Institute guidelines. Bacterial cells (5610 5 ml 21 ) were inoculated into MuellerHinton (MH) broth (100 ml) containing antibiotics with twofold serial dilutions. MICs were determined after culture at 35 uC for 18 h. All experiments were performed three times or more to confirm reproducibility.
Screening of MBL-producing bacterial strains by double-disc synergy test. To screen MBL-producing bacteria, a double-disc synergy test was performed by using discs containing CAZ, a thirdgeneration cephalosporin, and SMA, a specific inhibitor of MBLs. Following the inoculation of bacterial cells (2610 7 ) on an MH agar plate, a CAZ disc (Becton Dickinson) and a SMA disc (Eiken Chemical) were set with a distance of 1.5 cm between them. The plates were incubated at 35 uC for 24 h. When an obvious inhibition zone (.12 mm) was observed around the CAZ disc side facing the SMA disc, the strain was considered as an MBL producer.
Identification of resistance genes and associated integrons by PCR and DNA sequencing. Bacterial DNA was extracted using a SepaGene kit (Wako Pure Chemical Industries). The primer pair F intI1 -ACATGCGTGTAAATCATCGTCG/R sul1 -GTTTCCGAGAAGG-TGATTGCG was used for amplification of the genes between intI1 and sul1 (GenBank accession no. U49101). PCR was performed under the following conditions: 30 cycles of denaturation at 95 uC for 40 s, annealing at 58 uC for 60 s and extension at 72 uC for 60 s, followed by a final extension at 72 uC for 10 min. The amplicons were purified using a QIAquick PCR purification kit (Qiagen) and sequenced on an Applied Biosystems 3730xl DNA analyser. Nucleotide sequences were compared with the GenBank database via the BLAST network service.
Transfer of plasmids with resistance genes. E. coli HB101 (Wako Pure Chemical Industries) was used as recipient for conjugation. This strain is resistant to streptomycin, a property applied for the subsequent screening of transconjugants. Plasmids with resistance genes were transferred from wild-type E. coli and K. pneumoniae to E. coli HB101 with a donor/recipient ratio of 1 : 1 in Luria-Bertani (LB) broth at 37 uC for 2 h. Transconjugants were selected on LB agar plates containing cefotaxime (16 mg ml 21 ) and streptomycin (64 mg ml 21 ). Frequency of transfer was expressed as the ratio of the number of transconjugant cells to that of recipient cells per hour.
Pulsed-field gel electrophoresis (PFGE). PFGE of SpeI-digested genomic DNA from the tested bacterial strains was carried out using a CHEF-DRIII System (Bio-Rad) according to the manufacturer's instruction. The restriction patterns were evaluated according to a previously described standard (Tenover et al., 1995) . 
RESULTS
Genetic environment of bla IMP-11 and its transfer among bacteria
We identified three strains of E. coli and one strain of K. pneumoniae carrying the bla IMP-11 gene by PCR and DNA sequencing. bla IMP-11 was harboured by a typical class 1 integron which was composed of a 59-conserved segment (CS), a variable region and a 39-CS (Fig. 1) . The 59-CS contained intI1 (the gene encoding integrase), attI1 (the site adjacent to intI1 for the insertion of captured genes) and a P c promoter, TGGACA-N 17 -TAAACT. The 39-CS included a partially deleted qacED1 fused to the sul1 gene; these genes confer resistance to antiseptics and sulfonamide, respectively. The captured gene cassettes, bla IMP-11 , aacA1 and orfG, were inserted between the 59-CS and 39-CS. aacA1 encodes AAC(69)-I, an aminoglycoside 69-N-acetyltransferase, mediating resistance to AMK and KAN (Tenover et al., 1988) . Compared with the registered aacA1 (GenBank accession no. M18967), the aacA1 identified in this experiment has a silent mutation at nucleotide 42 with a single base substitution of T by C.
The integron, intI1-bla IMP-11 -aacA1-orfG-qacED1-sul1, was easily transferred by conjugation from wild-type strains of E. coli (E0702 and E0703) and K. pneumoniae (K0709) to E. coli HB101 at a frequency of 2. 8-12.4610 25 , indicating that the integron was carried by a transferable plasmid.
Amino acid identity and phylogeny of IMP-11 and other IMP variants
To compare the relatedness of IMP-11 and other IMPs, a phylogenetic tree was constructed according to their amino acid sequences. The deduced amino acid sequences of IMPs comprise 246 residues, with the exceptions of IMP-9, -11 and -21, which are composed of 245 residues. The identities of amino acid sequences of the IMP-11 and other IMP variants range from 81.3 to 99.6 %. IMP-21 is the nearest one to IMP-11, with one amino acid residue alteration, Val49Ala, and IMP-18 is the most divergent one, with 46 different amino acid residues (Fig. 2) .
Resistance phenotypes of the wild-type strains and transconjugants
The wild-type strains showed intermediate or low resistance to the carbapenems (MICs 0.5-8 mg ml
21
) and high resistance to CAZ (MICs 128-256 mg ml
). The serine b-lactamase inhibitor CAV failed to restore the activity of CAZ, but the MBL inhibitor SMA did ( Table 1 ), indicating that these strains are MBL producers. The transconjugants of E. coli HB101 showed similar resistance phenotypes to the wild-type donors (Table 1) . Owing to the acquisition of bla IMP-11 , the MICs of the carbapenems against the transconjugants increased 4-32-fold. These transconjugants Fig. 1 . Structure of the integron harbouring bla IMP-11 . The arrows indicate the direction of transcription. intI1, integrase 1 gene; P c , promoter; attI, attachment site; attC (i.e. the 59-base element), recognition site for the integrase; qacED1, quaternary ammonium resistance gene; sul1, sulphonamide resistance gene. Fig. 2 . Position of IMP-11 in the phylogenetic tree of the IMP family. DNASIS Pro v2.10 (Hitachi Software Engineering) was used to align the amino acid sequences and construct the phylogenetic tree. The horizontal branch lengths are drawn to scale and are proportional to the number of different amino acid residues. The distance along the vertical axis is of no significance. The scale bar represents 5 % amino acid difference.
also showed resistance to AMK and KAN (the MICs increased 16-32-fold) because they simultaneously obtained the aacA1 gene.
Nosocomial spread of the bla IMP-11 -positive strains
We analysed 20 MBL-producing clinical isolates collected from Showa University Northern Yokohama Hospital (661 beds) during September 2007 and August 2008. Of these isolates, 16 strains carried bla IMP-1 and four strains carried bla IMP-11 harboured by the identical integron, intI1-bla IMP-11 -aacA1-orfG-qacED1-sul1. All of the four strains with bla IMP-11 were isolated from stools of infant inpatients (Table 2 ). E. coli E0702 was the first bla IMP-11 -positive strain found since surveillance of MBL-producing bacteria in the hospital started in 2001. Twenty days later, E. coli E0703 was isolated from inpatient B. Two months later, K. pneumoniae K0709 was isolated from inpatient C. The three patients were hospitalized in the same paediatric ward. Eight months later, E. coli E0802 was isolated from inpatient D, who was hospitalized in a newborn infant ward next to the paediatric ward.
Genetic fingerprints of the three clinical isolates, E. coli E0702, E0703 and E0802, were analysed by PFGE. The chromosomal DNA restriction patterns indicated that they were genetically different. These results demonstrate the spread of the plasmid-and integron-borne bla IMP-11 and aacA1 in the hospital environment.
DISCUSSION
The emergence of MBL-associated integrons has become a significant clinical threat because the integrons are usually embedded in transposons, and in turn accommodated on plasmids, thereby constituting highly mobile genetic apparatus and facilitating their horizontal dissemination (Mazel, 2006; Zhao & Hu, 2011b) . In this study, we also confirmed that the bla IMP-11 gene was harboured by a class 1 integron located on a plasmid. The plasmid could be transferred easily between bacteria of the same species (E. coli to E. coli) and different genera (K. pneumoniae to E. coli), indicating the threat of nosocomial spread of the resistance determinants.
The integrated genes are usually expressed from a common promoter (P c ), which is located in an adjacent 59-CS. The bla IMP-11 and aacA1 genes were preceded by TGGACA-N 17 -TAAACT, a so-called hybrid P c promoter. Four different P c promoters have been described and their relative strengths have been compared to the E. coli tac promoter (Bunny et al., 1995; Stokes & Hall, 1989; Collis & Hall, 1995; Lévesque et al., 1994) . TTGACA-N 17 -TAAACT and TGGACA-N 17 -TAAGCT are described as strong and weak P c promoters, respectively. TTGACA-N 17 -TAAGCT and TGGACA-N 17 -TAAACT are described as hybrid promoters.
bla IMP-11 co-existed with aacA1 in the integron. The resistance phenotypes demonstrated the co-expression of IMP-11 and aminoglycoside 69-N-acetyltransferase AAC(69)-I, which enabled the bacteria to survive in the presence of not only carbapenems but also AMK and KAN (Table 1) . When several cassettes are present, however, co-existence of various resistance genes does not always imply the co-expression of all the genes. The expression of resistance genes is markedly influenced by their position in an integron. Newly acquired cassettes are highly expressed by the P c promoter, but they can be silenced by untimely recombination events that displace the cassettes to distal positions (Collis & Hall, 1995; Depardieu et al., 2007) . DPlasmid from E. coli E0702. dPlasmid from K. pneumoniae K0709.
The bla IMP-11 -positive bacteria should have spread widely since the integron bearing bla IMP-11 is located on a transferable plasmid and is readily transferred between bacteria. However, there are very limited reports on IMP-11-producing bacteria, and this is believed to be the first time that the genetic environment of bla IMP-11 has been described. There are several possible reasons for these inconsistent phenomena. First, an elevated MIC of the carbapenems is the first sign that a bacterial strain may be an MBL producer. However, the presence of MBL genes does not always confer resistance, especially in E. coli and K. pneumoniae. Compared to the very high MICs of carbapenems against MBL-producing S. marcescens (256-512 mg ml 21 for IPM; 128-2048 mg ml 21 for MEPM) and P. aeruginosa (32-2048 mg ml 21 for IPM; 128-4096 mg ml 21 for MEPM), as described previously Zhao et al., 2009) , the MICs against E. coli and K. pneumoniae in this study were 2-4 mg ml 21 for IPM and 8 mg ml 21 for MEPM (Table 1) . Therefore, some MBL producers may be missed if susceptibility to carbapenems alone is depended on. Second, although PCR analysis is the fastest method to determine the IMP variants, it is difficult to design a pair of universal primers for all IMPs. Third, DNA sequencing is required to distinguish bla IMP-11 from the other IMPs, but sequence analysis is highly specialized and beyond the scope of most clinical laboratories at present.
In conclusion, the occurrence and spread of plasmid-and integron-mediated IMP-type MBLs represents a significant challenge to clinicians and health authorities. It is necessary to survey the spread and colonization of bla IMP -harbouring bacteria in hospital environments. The IMP-associated integrons themselves may be used as molecular markers for epidemiological surveillance. 
